Inotiv, Inc. Launches Proposed Public Offering of Common Shares

Rhea-AI Summary

Inotiv (NOTV), a contract research organization focused on nonclinical and analytical drug discovery services, has announced a proposed underwritten public offering of common shares. The company will offer all shares and plans to grant underwriters a 30-day option to purchase up to 15% additional shares. Lake Street Capital Markets is serving as the sole book-running manager for the offering.

The offering is subject to market conditions, with no guarantee of completion or final terms. It will be conducted under a shelf registration statement on Form S-3 that was declared effective by the SEC on August 31, 2022.

Positive

• None.

Negative

• Potential shareholder dilution from new common share offering
• Uncertainty regarding offering completion and final terms

News Market Reaction

-28.83%

1 alert

-28.83% News Effect

On the day this news was published, NOTV declined 28.83%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

WEST LAFAYETTE, Ind., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced commencement of a proposed underwritten public offering of its common shares. All the shares will be offered by the Company. The Company also expects to grant the underwriters a 30-day option to purchase additional common shares in an amount of up to 15% of the number of shares sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Lake Street Capital Markets, LLC is acting as the sole book-running manager for the proposed offering.

A shelf registration statement on Form S-3 relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission (the “SEC”) on August 31, 2022. Before you invest, you should read the prospectus in the registration statement and related preliminary prospectus supplement that the Company filed with the SEC for more complete information about the Company and this offering. An electronic copy of the preliminary prospectus supplement and accompanying prospectus relating to the offering are available on the SEC website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the offering may also be obtained from Lake Street Capital Markets, LLC, Attn: Syndicate Department, 920 Second Avenue South, Suite 700, Minneapolis, MN 55402, by calling (612) 326-1305.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About the Company

Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world.

Forward-Looking Statements

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, statements regarding our expectations about the completion, terms, size and timing of the public offering, and with respect to granting the underwriter a 30-day option to purchase additional shares.  These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including risks and uncertainties related to completion of the public offering on the anticipated terms or at all, market conditions, the satisfaction of customary closing conditions related to the public offering, and those factors detailed in the Company's filings with the U.S. Securities and Exchange Commission. Further discussion of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in our Annual Report on Form 10-K as filed on December 4, 2024, as well as other filings we make with the Securities and Exchange Commission.

Company Contact	Investor Relations
Inotiv, Inc.	LifeSci Advisors
Beth A. Taylor, Chief Financial Officer	Steve Halper
(765) 497-8381	(646) 876-6455
Beth.Taylor@inotivco.com	shalper@lifesciadvisors.com

FAQ

What is the size of Inotiv's (NOTV) December 2024 public offering?

The exact size of the offering has not been disclosed in the announcement. The final size will depend on market conditions and other factors.

How many additional shares can underwriters purchase in Inotiv's (NOTV) offering?

Underwriters will have a 30-day option to purchase additional common shares up to 15% of the number of shares sold in the offering.

Who is the book-running manager for Inotiv's (NOTV) 2024 public offering?

Lake Street Capital Markets, is acting as the sole book-running manager for the proposed offering.

When was Inotiv's (NOTV) shelf registration statement declared effective?

The shelf registration statement on Form S-3 was declared effective by the SEC on August 31, 2022.